Electromyography ; Humans ; Occupational Health

Objective:To investigate the risk factors of preterm premature ruPture of membrane(PPROM) and their pregnancy outcomes.Methods:The clinical data of 95 cases of patients with PPROM admitted and treated in our hospital from October 2013 to July 2016 were collected,which were divided into two groups,observation group(gestational week 28-33 +6 weeks) and control group(gestational week 34-36 +6 weeks).The risk factors of PPROM,delivery method and pregnancy outcomes were analyzed.Results:Genital tract infection was the main risk factor of PPROM(33.68％).of the incidences of cesarean delivery,neonatal asphyxia,neonatal infections and neonatal death in observation group were significantly higher than those of control group,the differences were statistically significant(P ＜ 0.05).The intrauterine infection and puerperal infection rates of observation group of were higher than those of control group,but differences were not statistically significant (P ＞ 0.05).Conclusions:Reproductive tract infections is the most important risk factor of PPROM.The purpose of active treatment including tocolytic therapy and prevention of infection for the patients with PPROM less than 34 weeks is to prolong the gestational weeks,to reduce the rate of neonatal complication,and to improve the pregnancy outcome.

Objective:To study the expression of Pleiotrophin and Midkine protein in endometrium of endometriosis and its clinical significance.Methods:Expressions of Pleiotrophin and Midkine protein were examined by immunohistochemical staining method in 30 endometrial samples of endometriosis(study group) and 29 endometrium of uterine fibroid(control group).Result:Pleiotrophin protein mainly expressed in the membrane and plasma of glandular epithelium of endometrium.Midkine protein mainly expressed in the plasma of grandular epithelium of endometrium and expressed in nuclei in some samples.The expression of Pleiotrophin and Midkine protein in endometriosis was significantly higher than that in the control group(P

Aging ; Arteriosclerosis ; pathology ; Blood Vessels ; pathology ; Cellular Senescence ; Humans ; Medicine, Chinese Traditional

Diabetes Mellitus, Type 2 ; drug therapy ; Humans ; Hypoglycemic Agents ; therapeutic use ; Non-alcoholic Fatty Liver Disease ; drug therapy

Objective To learn the prevelance of Acinetobacter baumannii and its drug resistance related with Ⅰ class integron. Methods 22 kinds of antibiotics commonly used in our hospital were used to detect the sensitivity of the clinically separated Acineto-bacter baumannii.Methods PCR was used to detect Ⅰ class integron enzyme gene of Acinetobacter baumannii,and then parts of variable region of Ⅰ class integron enzyme gene were amplified and analyzed for gene sequence.Results The drug resistance of Acinetobacter baumannii phenomenon was very serious,which was multiple drug resistance.The resistance rate of Acinetobacter baumannii to CPZ/SB was 1.2%.And the resistance rates to tigecycline,ofloxacin,imipenem,biapenem,and amikacin were 1 5.4%-69.5%,but the resistance rates to other antibiotics were above 71%.There were 72 of 102 strains including Ⅰ class integron (positive rate was 70.2%).The resistance of strains with Ⅰ class integron was stronger than that of the strains without.The varia-ble area of Ⅰ class integron produced the same enzyme bands when analyzed with double enzyme,suggesting the Acinetobacter bau-mannii was homologous.The gene sequence analysis of Ⅰ class integron showed that the Ⅰ class integron of the Acinetobacter bau-mannii carried kinds of resistant genes such as aacA4,catB8 and aadA13.Conclusion From 2010 to 2013,the Acinetobacter bau-mannii in our hospital is highly resistant to cephalosporins,broad-spectrum penicillin,aminoglycosides and fluoroquinolones and is severely multiple drug resistant.So the antimicrobial drugs for the treatment of infections caused by Acinetobacter baumannii are limited.Ⅰ class integron is closely related to the multiple drug resistance of Acinetobacter baumannii.

Choroidal neovascularization( CNV) is a common severe complication of ocular fundus diseases, with great potentiality to cause blindness. The treatments of CNV include photodynamic therapy ( PDT ) and anti-vascular endothelial growth factor( VEGF) therapy. However, PDT produces little visual benefits, and may result in ischemia, inflammatory responses, even the secondary expressions of VEGF. Anti-VEGF therapy sustained visual efficiency by repeated injections, causing economic burden and adverse effects related to injection. Recently, PDT combined with anti-VEGF therapy has progressed in laboratory and clinical research. Therefore, the combined modality therapy became one of the treatment options for CNV. In order to reduce the side effects of mono -therapy, further study is required to determine appropriate combinations and dosage.

OBJECTIVE:To explore the treatment effect and complication prevention of various stent materials for intracranial arteriostenosis.METHODS:A computer-based online search of Science Direct and Ei database (1998-01/2009-10) was performed for English articles with the key words of "intracranial arteriostenosis,stent placement" In addition,CNKI and CBM database (1998-01/2009-10) were searched for related Chinese articles with the same key words in Chinese.Moreover,related works were manually searched.Studies regarding various stent materials for intracranial arteriostenosis were included,including basic and clinical experiments.RESULTS:Multicenter studies of worldwide show that stent implantation displays obvious advantages in treating carotid artery stenosis compared with carotid endarterectomy.Recently,with developing of balloon and stent compliance,as well as stent technology,and application of various novel materials and cerebral protection device,stent has become a safe and effective therapy for intracranial arteriostenosis.However,complications following stent implantation,such as restenosis,ischemic stroke,cerebral hemorrhage hypertransfusion syndrome,and cerebral angiospasm,limit its application.CONCLUSION:The safety and efficacy of intracranial stent implantation remains validation of multicenter and perspective studies.High incidence of restenosis following stent implantation requires further improvement.

Objective To study the effect of acarbose on vascular endothelial function in patients with impaired glucose tolerance (IGT).Methods Fifty-six cases with IGT were chosen by OGTT,and they were divided into control group(27 cases) and therapy group(29 cases) by systematic sampling.The patients in control group were received placebo,the patients in therapy group were given acarbose 25-50 rug,3 times daily for 12 weeks.The body mass index (BMI),blood fat,fasting blood glucose (FPG),fasting insulin (FINS),glycosylated hemoglobin (HbA1c),high sensitivity C-reactive protein (hs-CRP),von Willebrand factor (vWF),2 h post-meal glucose (2hPG),2 h post-meal insulin (2hINS) and brachial artery endothelium-dependent dilation (EDD) was detected before and after treatment in two groups.Results Compared with that before treatment,BMI,2hPG,2hINS,HbA1c,hs-CRP and vWF were decreased and brachial artery EDD was improved after treatment in therapy group[ (24.69 ± 2.62) kg/m2 vs.(22.02 ± 2.59)kg/m2,(9.26 ± 1.02) mmol/L vs.(7.43 ± 0.95) mmol/L,(42.17 ± 9.98) U/L vs.(34.76 ± 9.86) U/L,(6.03 ±0.67)％ vs.(5.37 ±0.56)％,(5.45 ± 1.93) mg/L vs.(4.52 ± 1.55) mg/L,(187.22 ±26.57)％ vs.(165.13 ± 23.86)％,(6.08 ± 1.22)％ vs.(7.94 ± 1.25)％ ] (P ＜ 0.05 or ＜ 0.01).There was no significant difference before and after treatment in control group (P ＞ 0.05).Conclusion Acarbose can improve brachial artery EDD in patients with IGT by increasing insulin sensitivity and decreasing postprandial hyperglycemia and inflammatory factor,which delays the progression of diabetic mellitus and atherosclerosis.

Nonunion or delayed union remains one of the major complicatio ns of fractures. Repair of fractures involves a sequence of dynamic events which ultimately restore the integrity of bone and its biomechanical properties, incl uding such methods as surgery, internal fixation, bone grafting, external fixati on, electrical stimulation, ultrasound, and high-energy extracorporeal shock wa ve. The preferred management of nonunion and delayed union is autologous bone gr afting. However, the supply of suitable bone is limited and it often results in additional morbidity to the donor site. Recently some advances have been made in the therapeutic principle for nonunion or delayed union. It is aimed at providi ng non-invasion, less complication, and safe treatment. This article introduces the development of some effective and safe therapies for nonunion or delayed un ion.